The Key Role of RNA Modification in Breast Cancer

Liu, Yang; Zhu, Tong Yin; Jiang, Yi; Bu, Jiawen; Zhu, Xudong; Gu, Xi

doi:10.3389/fcell.2022.885133

Cited by 5 publications

(3 citation statements)

References 119 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[144] miR-210 m6A modification MIR210HG fosters BC progression through IGF2BP1-mediated m6A modification [82] let-7b-5pmiR-195-5pmiR-29a-3pmiR-26a-5pmiR-26b-5p m5C modification Identified as upstream miRNA in the prognostic signature. Implicated in BC pathology [146] predominant reliance on cell line studies, making translation to diverse BC subtypes a complex task. The intricate secondary and tertiary structures of lncRNAs may compromise the efficacy of therapeutics targeting them.…”

Section: Mirna Expression Undergoes Rigorous Regulation At Both Trans...mentioning

confidence: 99%

Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs

Yin,

Qu,

Mathew

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Breast cancer (BC) poses a persistent global health challenge, particularly in countries with elevated human development indices linked to factors such as increased life expectancy, education, and wealth. Despite therapeutic progress, challenges persist, and the role of epitranscriptomic RNA modifications in BC remains inadequately understood. The epitranscriptome, comprising diverse posttranscriptional modifications on RNA molecules, holds the potential to intricately modulate RNA function and regulation, implicating dysregulation in various diseases, including BC. Noncoding RNAs (ncRNAs), acting as posttranscriptional regulators, influence physiological and pathological processes, including cancer. RNA modifications in long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) add an extra layer to gene expression control. This review delves into recent insights into epitranscriptomic RNA modifications, such as N‐6‐methyladenosine (m6A), adenine‐to‐inosine (A‐to‐I) editing, and 5‐methylcytosine (m5C), specifically in the context of lncRNA and miRNAs in BC, highlighting their potential implications in BC development and progression. Understanding this intricate regulatory landscape is vital for deciphering the molecular mechanisms underlying BC and identifying potential therapeutic targets.

show abstract

Section: Mirna Expression Undergoes Rigorous Regulation At Both Trans...mentioning

confidence: 99%

Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs

Yin,

Qu,

Mathew

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…The modulation of breast cancer through RNA m6A modification has been the subject of extensive research. This modification orchestrates the proliferation, invasion, and metastasis of breast cancer by effecting changes in diverse signaling pathways [ 68 ]. However, existing research on the influence of m1A in breast cancer remains insufficient.…”

Section: M1a and Cancermentioning

confidence: 99%

Research progress of N1-methyladenosine RNA modification in cancer

Liu,

Zhang,

Gao

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

N1-methyladenosine (m1A) is a post-transcriptionally modified RNA molecule that plays a pivotal role in the regulation of various biological functions and activities. Especially in cancer cell invasion, proliferation and cell cycle regulation. Over recent years, there has been a burgeoning interest in investigating the m1A modification of RNA. Most studies have focused on the regulation of m1A in cancer enrichment areas and different regions. This review provides a comprehensive overview of the methodologies employed for the detection of m1A modification. Furthermore, this review delves into the key players in m1A modification, known as the “writers,” “erasers,” and “readers.” m1A modification is modified by the m1A methyltransferases, or writers, such as TRMT6, TRMT61A, TRMT61B, TRMT10C, NML, and, removed by the demethylases, or erasers, including FTO and ALKBH1, ALKBH3. It is recognized by m1A-binding proteins YTHDF1, TYHDF2, TYHDF3, and TYHDC1, also known as “readers”. Additionally, we explore the intricate relationship between m1A modification and its regulators and their implications for the development and progression of specific types of cancer, we discuss how m1A modification can potentially facilitate the discovery of novel approaches for cancer diagnosis, treatment, and prognosis. Our summary of m1A methylated adenosine modification detection methods and regulatory mechanisms in various cancers provides useful insights for cancer diagnosis, treatment, and prognosis.

show abstract

“…Analysis of BC data in ONCOMINE revealed changes in the transcript levels of writers, readers, and erasers of the most common RNA modification, N-6methyladenosine (m6A) with two readers, RBM15B and ZC3H13, positively associated with ER and PR expressions and with longer relapse-free survival (RFS) (Zhang et al 2020). However, there are conflicting data with respect to associations of these and other m6A writers, readers, and erasers in BC (Liu et al 2022a). There are few studies on how the position of m6A affects transcript splicing, stability, or translation in BC cells or tumors, indicating the need for closer examination of the importance of the regulation of the epitranscriptome in subtype-specific BC and metastatic disease.…”

Section: Introductionmentioning

confidence: 99%

m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer

Petri

Klinge

2023

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Epitranscriptomic modification of RNA regulates human development, health, and disease. The true diversity of the transcriptome in breast cancer including chemical modification of transcribed RNA (epitranscriptomics) is not well understood due to limitations of technology and bioinformatic analysis. N-6-methyladenosine (m6A) is the most abundant epitranscriptomic modification of mRNA and regulates splicing, stability, translation, and intracellular localization of transcripts depending on m6A association with reader RNA binding proteins. m6A methylation is catalyzed by the METTL3 complex and removed by the specific m6A demethylase ALKBH5, with FTO’s role as an ‘eraser’ uncertain. In this review, we provide and overview of epitranscriptomics related to mRNA and focus on m6A in mRNA and its detection. We summarize current knowledge on altered levels of writers, readers, and erasers of m6A and their roles in breast cancer and association with prognosis. We summarize studies identifying m6A peaks and sties in genes in breast cancer cells.

show abstract

The Key Role of RNA Modification in Breast Cancer

Cited by 5 publications

References 119 publications

Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs

Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs

Research progress of N1-methyladenosine RNA modification in cancer

m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer

Contact Info

Product

Resources

About